PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to treat infections in chronic and acute wounds, announced today an agreement with Bayer Taiwan Co. Ltd. for development of the Microcyn® Technology for use in the Taiwanese animal market.
